Journal of Shandong University (Health Sciences) ›› 2019, Vol. 57 ›› Issue (10): 107-111.doi: 10.6040/j.issn.1671-7554.0.2019.691

Previous Articles     Next Articles

Effects of serum levels of sEGFR, CEA and Cyfra21-1 on the prognosis of non-small cell lung cancer patients

XU Shuyuan, JI Quanjiang, GUO Li   

  1. Department of Clinical Laboratory, Affiliated Hospital of Shandong Academy of Medical Sciences, Shandong First Medical University, Jinan 250031, Shandong, China
  • Published:2022-09-27

PDF (PC)

204

Abstract: Objective To investigate the correlation between the expression levels of serum soluble epidermal growth factor receptor(sEGFR), carcinoembryonic antigen(CEA), cytokeratin 19 fragment(Cyfra21-1), and overall survival of patients with non-small cell lung cancer(NSCLC). Methods Altogether 127 NSCLC cases were involved, including 42 cases of squamous carcinoma and 85 cases of adenocarcinoma. The TNM stage was II+III in 45 cases and IV in 82 cases. The sEGFR expression was detected with ELISA, and CEA and cyfra21-1 levels were detected with electrochemical luminescence. The relationship between the levels of sEGFR, CEA, Cyfra21-1 and the clinicopathological characteristics and prognosis of NSCLC patients were analyzed. Results The expressions of sEGFR and CEA in NSCLC patients were correlated with the clinical stage (P<0.05). Patients with adenocarcinoma showed significantly higher CEA than patients with squamous carcinoma (P<0.05), while serum Cyfra21-1 had no statistically significant characteristics (P>0.05). The median survival of patients with reduced serum sEGFR, increased CEA, and increased Cyfra21-1 was 9.0(4.0-21.25)months, 8.5(4.0, 16.0)months and 8.0(4.0, 13.25)months, respectively, which were statistically significant compared with patients with normal expressions (P<0.05). Conclusion The decrease of sEGFR, increase of CEA and Cyfra21-1 in patients with NSCLC is significantly correlated with the overall survival, and the prognosis can be assessed by detecting the serum levels of sEGFR, CEA and Cyfra21-1. 山 东 大 学 学 报 (医 学 版)57卷10期 -徐淑媛,等.血清sEGFR、CEA及Cyfra21-1水平对非小细胞肺癌患者预后的影响 \=-

Key words: Non-small cell lung cancer, Soluble epidermal growth factor receptor, Carcinoembryonic antigen, Cytokeratin 19 fragment, Prognosis

CLC Number: 

  • R734.2
[1] 仰杰, 尤青海, 孟凡亮, 等. 非小细胞肺癌miR-211表达与功能初步研究[J]. 中华肿瘤防治杂志, 2018, 25(11): 773-777. YANG Jie, YOU Qinghai, MENG Fanliang, et al. Expression and function of miR-211 in non-small cell lung cancer [J]. Chinese Journal of Cancer Prevention and Treatment, 2018, 25(11): 773-777.
[2] Ye S, Chen X, Yao Y, et al. Thioredoxin reductase as a novel and efficient plasma biomarker for the detection of non-small cell lung cancer: a Large-scale, Multicenter study [J]. Sci Rep, 2019, 9(1): 2652.
[3] 吕丽婷, 刘益飞, 刘军, 等. EHD2在非小细胞肺癌中的表达及其临床意义[J]. 实用医学杂志, 2017, 33(22): 3769-3772. LV Liting, LIU Yifei, LIU Jun, et al. EHD2 expression and clinical significance in non-small cell lung cancer [J]. The Journal of Practical Medicine, 2017, 33(22): 3769-3772.
[4] 周婉婉, 梁冰, 王效静, 等. 非小细胞肺癌患者外周血hTERT mRNA水平检测的临床意义[J]. 东南大学学报(医学版), 2017, 36(2): 217-221. ZHOU Wanwan, LIANG Bing, WANG Xiaojing, et al. The level of hTERT mRNA in peripheral blood of non-small cell lung cancer detected by real-time PCR [J]. Journal Southeast University(Medical Science Edition), 2017, 36(2): 217-221.
[5] Zhang L, Liu D, Li L, et al. The important role of circulating CYFRA21-1 in metastasis diagnosis and prognostic value compared with carcinoembryonicantigen and neuron-specific enolase in lung cancer patients [J]. BMC Cancer, 2017, 17(1): 96. doi: 10.1186/s12885-017-3070-6.
[6] Detterbeck FC, Boffa DJ, Kim AW, et al. The eighth edition lung cancer stage classification [J]. Chest, 2017, 151(1): 193-203.
[7] Xu CH, Yang Y, Wang YC, et al. Prognostic significance of serum chemerin levels in patients with non-small cell lung cancer [J]. Oncotarget, 2017, 8(14): 22483-22489.
[8] Shigehiro Y, Hidehito H, Kuniko SS, et al. Impact of KRAS mutation on response and outcome of patients with stage III non-squamous non-small cell lung cancer [J]. Cancer Sci, 2015,106(10): 1402-1407.
[9] Wang N, Guo H, Dong Z, et al. Establishment and validation of a 7-microRNA prognostic signature for non-small cell lung cancer [J]. Cancer Manage Res, 2018, 12(10): 3463-3471.
[10] Wang J, Jiang W, Zhang T, et al. Increased CYFRA 21-1, CEA and NSE are prognostic of poor outcome for locally advanced squamous cell carcinoma in lung: a nomogram and recursive partitioning risk stratificantion analysis[J]. TranslOncol, 2018, 11(4): 999-1006.
[11] Singh P, Srivastava AN, Sharma R, et al. Circulating MicroRNA-21 expression as a novel serum biomarker for oral sub-mucous fibrosis and oral squamous cell carcinoma[J]. Asian Pac JCancer Prev, 2018, 19(4): 1053-1058.
[12] He Y, Cui Y, Chang D, et al. Postoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I pulmonary adenocarcinoma[J]. Oncotarget, 2017, 8(42): 73115-73122.
[13] Jin J, Si J, Liu Y, et al. Elevated serum soluble programmed cell death ligand 1 concentration as a potential marker for poor prognosis in small cell lung cancer patients with chemotherapy[J]. Respir Res, 2018, 19(1): 197. doi: 10.1186/s12931-018-0885-x.
[14] 冯晓云, 葛琴, 陆志斌. 非小细胞肺癌患者血清miR-133b的表达水平及其临床意义探讨[J].东南大学学报(医学版), 2015, 34(6): 934-937. FENG Xiaoyun, GE Qin, LU Zhibin. Serum miR-133b levels and its relation with clinical pathological characteristics in non-small cell lung cancer patients[J]. Journal of Southeast University(Medical Science Edition), 2015, 34(6): 934-937.
[15] Zhu W, Zhou K, Zha Y, et al. Diagnostic value of serum miR-182, miR-183, miR-210, and miR-126 levels in patients with early-stage non-small cell lung cancer[J]. PLoS ONE, 2016, 11(4): e0153046. doi: 10.1371/journal.pone.0153046.
[16] Liu AM, Zhu Y, Huang ZW, et al. Long noncoding RNA FAM201A involves in radioresistance of non-small-cell lung cancer by enhancing EGFR expression via miR-370[J]. Eur Rev Med Pharmacol Sci, 2019, 23(13): 5802-5814.
[17] Filippo L, Massimiliano P, Cristian R, et al. Preliminary evidence on the diagnostic and molecular role of circulating soluble EGFR in non-small cell lung cancer[J]. Mol Sci, 2015, 16(8): 19612-19630.
[18] Hui R, Yang H, Tao X, et al. Effect of gefitinib on serum EGFR and CYFRA21-1 in patients with advanced non-small cell lung cancer[J]. Oncol Lett, 2019, 18(4): 4167-4175.
[19] Romero-Ventosa EY, Blanco-Prieto S, González-Pi(~overn)eiro AL, et al. Pretreatment levels of the serum biomarkers CEA, CYFRA 21-1, SCC and the soluble EGFR and its ligands EGF, TGF-alpha, HB-EGF in the prediction of outcome in erlotinib treated non-small-cell lung cancer patients [J]. Springer Plus, 2015, 9(4): 171. doi: 10.1186/s40064-015-0891-0. eCollection 2015.
[20] Dai L, Qu Y, Li J, et al. Serological proteome analysis approach-based identification of ENO1 as a tumor-associated antigen and its autoantibody could enhance the sensitivity of CEA and CYFRA 21-1 in the detection of non-small cell lung cancer [J]. Oncotarget, 2017, 8(22): 36664-36673.
[21] Dal Bello MG, Filiberti RA, Alama A, et al. The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer(NSCLC)patients [J]. J Transl Med, 2019, 17(1): 74. doi: 10.1186/s12967-019-1828-0.
[22] Mauro C, Passerini R, Spaggiari L, et al. New and old biomarkers in the differential diagnosis of lung cancer: pro-gastrin-releasing peptide in comparison with neuron-specific enolase, carcinoembryonic antigen, and CYFRA 21-1 [J]. Int J Biol Markers, 2019, 34(2):163-167.
[23] Wang XB, Li J, Han Y. Prognostic significance of preoperative serum carcinoembryonic antigen in non-small cell lung cancer: a metaanalysis[J]. Tumor Biol, 2014, 35(10): 10105-10110.
[24] Baek AR, Seo HJ, Lee JH, et al. Prognostic value of baseline carcinoembryonic antigen and cytokeratin 19 fragment levels in advanced non-small cell lung cancer [J]. Cancer Biomarker, 2018, 22(1): 55-62.
[25] Parka SY, Leea JG, Kimb J, et al. Preoperative serum CYFRA 21-1 level as a prognostic factor in surgically treated adenocarcinoma of lung [J]. Lung Cancer, 2013, 79(2): 156-160.
[1] HUANG Peiwen, WANG Xudong. A new drug for non-small cell lung cancer: Telisotuzumab Vedotin, an antibody-drug conjugate targeting c-Met protein [J]. Journal of Shandong University (Health Sciences), 2026, 64(3): 124-130.
[2] LI Ziqi, WEI Yanruoxue, LIU Xiaohan, LIU Chuncheng, ZHAO Ran, LIU Yukun. The functional role and clinical significance of lncRNA HEATR3-AS1 in colorectal cancer tumorigenesis and progression [J]. Journal of Shandong University (Health Sciences), 2025, 63(9): 108-115.
[3] LIU Baoguo, SONG Xiang, ZHAO Xiaowen, MAO Yali. Application value of serum STAT5B and NKAIN1 mRNA detection in breast cancer [J]. Journal of Shandong University (Health Sciences), 2025, 63(7): 68-74.
[4] WANG Lei, CHANG Xiao, WANG Zimeng, LI Jiaojiao, CUI Shujun, YANG Fei, ZHU Yuexiang. Predictive value of intratumoral and peritumoral DCE-MRI imaging histology for progression-free survival in patients with cervical cancer [J]. Journal of Shandong University (Health Sciences), 2025, 63(6): 45-54.
[5] JIA Ruoxi, LYU Li, LIU Hanyun, WU Yinping, LI Fengcai, ZHAO Zehua, WANG Kai, FAN Yuchen. Diagnostic value of blood cell count-related biomarkers in predicting 28-day mortality in acute-on-chronic hepatitis b liver failure [J]. Journal of Shandong University (Health Sciences), 2025, 63(6): 89-99.
[6] ZHAO Hanqing, ZHOU Xinrui, LI Zijian, TANG Xing. Application of circulating tumor cells combined with serological detection in non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2025, 63(5): 79-85.
[7] DU Xue, LI Chunxia, LIU Yunxia, ZHANG Tao. Dynamic prediction model for the colorectal cancer patients prognosis based on MFPC-Cox [J]. Journal of Shandong University (Health Sciences), 2025, 63(5): 101-110.
[8] YANG Weifang, XU Hong, LIU Yuantao, ZHAO Huichen. Mechanism of thyroid-stimulating immunoglobulin in Graves disease recurrence and clinical significance [J]. Journal of Shandong University (Health Sciences), 2025, 63(4): 116-121.
[9] XU Nianxing, WEI Dong, QIAO Junjie, ZHAN Bingyan. Predictive value of CD8+, IL-6, and PaO2 for immunotherapy-triggered radiation recall pneumonitis in unresectable stage ⅢB/C and IV non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2025, 63(2): 29-35.
[10] Thoracoscopic Committee of Shandong Provincial Endoscopic Surgery Quality Control Center. Shandong Provincial expert consensus on control indexes of VATS/RATS perioperative quality for non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2025, 63(12): 1-5.
[11] LIU Wenzhao, ZHANG Yuan, MA Xiangping, WEI Fengtao, BU Peili. Correlation between the pre-endothelial activation and stress index and the mortality risk of patients with heart failure [J]. Journal of Shandong University (Health Sciences), 2025, 63(11): 27-35.
[12] LIU Zhenkun, LYU Jiling, XU Weiwei, MA Litian, ZHANG Caiqing. Value of tNGS testing and conventional culture for BALF in the diagnosis of NSCLC complicated with IPFD [J]. Journal of Shandong University (Health Sciences), 2025, 63(11): 36-45.
[13] CHEN Wenliang, WANG Huanhuan, HAO Jinjin, GONG Rui, ZHAO Qiang, ZHANG Fei, GAO Lei, DONG Jingxun. The role of lncRNA PVT1 in prognostic assessment and malignant progression of gastric cancer: a study based on nomogram model and functional cellular experiments [J]. Journal of Shandong University (Health Sciences), 2025, 63(10): 61-71.
[14] GUO Shuhua, FAN Yang, TIAN Feng, WANG Chuanxin, DU Lutao, LI Peilong, GUO Xing, XU Shuo. Role of microfibril-associated protein 3 in regulating mesenchymal transition of glioma stem cells [J]. Journal of Shandong University (Health Sciences), 2024, 62(6): 9-16.
[15] WEI Yanruoxue, LI Ziqi, LIU Chuncheng, LIU Xiaohan, ZHAO Ran, LIU Yukun. Intratumor heterogeneity of SP1 expression in colorectal cancer and its clinical significance [J]. Journal of Shandong University (Health Sciences), 2024, 62(5): 89-94.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd